Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pediatric Exclusivity 90-Day Review Can Be “Difficult” Target – Kweder

Executive Summary

FDA sometimes is challenged to meet the deadline for completing the review of whether a drug sponsor's clinical trials in children qualify a product for pediatric exclusivity, Office of New Drugs Deputy Director Sandra Kweder indicated May 22

You may also be interested in...



Pediatric Exclusivity Breaks 3-Month Cap In House, But Still Must Find Offset

The legislation to renew the pediatric exclusivity language in the House now provides six months for all products as opposed to the sales-tiered incentives in the Senate bill, but the more generous offer serves to underline the challenge to the program - finding an offset to pay for it

Pediatric Exclusivity Breaks 3-Month Cap In House, But Still Must Find Offset

The legislation to renew the pediatric exclusivity language in the House now provides six months for all products as opposed to the sales-tiered incentives in the Senate bill, but the more generous offer serves to underline the challenge to the program - finding an offset to pay for it

FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines

Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa

Related Content

UsernamePublicRestriction

Register

PS048411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel